SCHEMBL23069167

SCHEMBL23069167

Cc1cc(Oc2ccnc(N)n2)ccc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 2/20 0.44
KDM4E B2RXH2 2/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HPGD P15428 1/20 0.40
KDR P35968 4/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HRH4 Q9H3N8 1/20 0.38
FLT1 P17948 2/20 0.38
FLT4 P35916 2/20 0.38
RET P07949 1/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
SCN9A Q15858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4795261 0.88 KDM4E (0.41) KDM4EPOLBMAPTSMN1; SMN2MEN1
SCHEMBL4938557 0.86 KDM4E (0.47) KDM4EPOLBMAPTSMN1; SMN2MEN1
SCHEMBL21610195 0.81 DHFR (0.47) NUDT1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL2025837 0.78 KDR (0.45) NUDT1MEN1KMT2AKDRFLT1
SCHEMBL31403749 0.77 MAP4K4 (0.51) NUDT1MEN1KMT2AKDRNPC1
SCHEMBL1892428 0.76 MEN1 (0.50) NUDT1KDM4EPOLBMAPTSMN1; SMN2
SCHEMBL4795862 0.76 MAP4K4 (0.41) KDM4EPOLBMAPTSMN1; SMN2MEN1
SCHEMBL4797753 0.76 DRD1 (0.49) KDM4EPOLBMAPTMEN1KMT2A
SCHEMBL4883357 0.76 AXL (0.51) NUDT1KDRFLT1FLT4RET
SCHEMBL4328013 0.76 NOS3 (0.55) KDM4EPOLBMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220306640-A1 HYDANTOIN DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2022-09-29 US disclosed
EP-4025570-A1 HYDANTOIN DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2022-07-13 EP disclosed
WO-2021043245-A1 HYDANTOIN DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2021-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306640-A1 HYDANTOIN DERIVATIVE DDR1, DDR2, DDRGK1 NUDT1 691/4885KDM4E 1968/4885POLB 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.